Myeloproliferative neoplasm surgery

Jump to navigation Jump to search

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm surgery

on Myeloproliferative neoplasm surgery

Myeloproliferative neoplasm surgery in the news

Blogs on Myeloproliferative neoplasm surgery

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Surgical intervention is usually not recommended for the management of chronic myelogenous leukemia, unless there is splenomegaly.

Surgery

Surgical intervention is rarely recommended for the management of chronic myelogenous leukemia in case of splenomegaly.[1] There is generally no role for surgery.

References

  1. Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R; et al. (2014). "Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation". Leuk Lymphoma. 55 (1): 121–7. doi:10.3109/10428194.2013.794269. PMC 3874259. PMID 23573823.

Template:WH Template:WS